HR Execs on the Move

Arcutis

www.arcutis.com

 
Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.arcutis.com
  • 3027 Townsgate Road Suite 300
    Westlake Village, CA USA 91361
  • Phone: 805.418.5006

Executives

Name Title Contact Details
David Topper
 Chief Financial Officer Profile
Todd Edwards
 Chief Commercial Officer Profile
Scott Burrows
 Chief Financial Officer Profile
John Smither
 Interim Chief Financial Officer Profile
Don Plummer
 R&D Chief of Staff & Clinical Integration Profile

Similar Companies

Novan Therapeutics

Novan is a clinical-stage drug development company focused on topical delivery of nitric oxide. The company`s proprietary platform technology enables the stable storage and release of nitric oxide in a variety of dosage forms. Novan is currently developing innovative, first-in-class therapies for the field of dermatology.

EnviroLogix

Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.

great healthworks

great healthworks is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.

Palvella Therapeutics

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.